Abstract
Disturbances in cardiac rhythm or rate are common in patients with heart failure. The symptom of palpitations can be defined as either forceful or rapid beating of the heart. This frequent complaint among patients may be associated with a variety of arrhythmias, including all forms of tachycardias (supraventricular and ventricular), ectopic beats, compensatory pauses, or alterations of cardiac outputs. The perception of “palpitations” is highly individualized and may not always suggest a diagnosis of tachycardia. In the case of premature contractions, the patient is usually more aware of the postextrasystole beat augmentation than the premature beat itself. Nonsustained ventricular tachycardia, for example, is often asymptomatic.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Crawford MH, Bernstein SJ, Deedwania PC, et al. ACC/AHA Guidelines for ambulatory electrocardiography: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the guidelines for ambulatory electrocardiography). Circulation 1999;100:886–893.
Cheitlin MD, Garson A, Gibbons RJ, et al. ACC/AHA guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. Circulation 1995;92:675–691.
Krahn AD, Klein GJ, Yee R, et al. Randomized assessment of syncope trial: Conventional diagnostic testing versus prolonged monitoring strategy. Circulation 2001;104:46–51.
Stevenson WG, Ganz LI. Atrial fibrillation in heart failure. Heart Failure 1997;13:22–29.
Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: Population-based estimation. Am J Cardiol 1998;82:2N-9N.
Saxon LA. Atrial fibrillation and dilated cardiomyopathy: therapeutic strategies when sinus rhythm cannot be maintained. PACE 1997;20:720–725.
Shinbane JS, Wood MA, Jensen N, et al. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709–715.
Middlekauff HR, Stevenson WG and Stevenson LW, Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991;84:40–48.
Aberg H. Atrial fibrillation: a study of atrial thrombosis and systemic embolism in a necropsy material. Acta Med Scand 1969;185:373–379.
Manning WJ, Silverman DI, Keighley CS, et al. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation suing short-term anticoagulation: final results of a prospective 4.5-year study. J Am Coll Cardiol 1995;25:1345–1361.
Nademanee K, Kosar EM. Long-term antithrombotic treatment for atrial fibrillation. Am J Cardiol 1998;82:37N-42N.
Wolf PA, Abbott RD, Kanne! WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983–988.
Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175–179.
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527–539.
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990 323:1505–1511.
Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 18:349–355.
Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406–1412.
Halperin JL, Hart RG, Kronmal RA, et al. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687–691.
Laupacis A, Albers G, Dalen J, et al. Antithrombotic therapy in atrial fibrillation. Chest 1995;108:352S-359S.
Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Eng! J Med 1996;335:540–546.
Koudstaal P, The European Atrial Fibrillation Trial Study. Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5–10.
Tischler MD, Lee TH, McAndrew KA, et al. Clinical, echocardiographic and Doppler correlates of clinical instability with onset of atrial fibrillation. Am J Cardiol 1990;66:721–724.
Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954–1968.
Daoud EG, Bogun F, Goya! R, et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996;94:1600–1606.
Yu WC, Chen SA, Lee SH, et al. Tachycardia-induced change in atrial refractory period in humans. Rate dependency and effects of antiarrhythmic drugs. Circulation 1998;97:2331–2337.
Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990;82:1106–1116.
Chatterjee K, Demarco T, Saxon LA, et al. Antiarrhythmic drug therapy for atrial fibrillation in dilated cardiomyopathy. Heart Failure 1997;13:7–21.
Pratt CM, Eaton T, Francis M, et al. The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio. Am Heart J 1989;118:433–440.
Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781–788.
Flaker GC, Blackshear JL, McBride R, et al. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardio! 1992120:527–532.
Teo KK, Yusuf S and Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993 1270:1589–1595.
Waldo AL and Prystowsky EN. Drug treatment of atrial fibrillation in the managed care era. Am J Cardiol 1998181:23C-29C.
Keane D, Zou L and Ruskin J. Non-pharmacologic therapies for atrial fibrillation. Am J Cardiol 1998181:41C-45C.
Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998;339:659–666.
Chen SA, Hsieh MH, Tai CT, et al. Initiation of atrial fibrillation by ectopic beats originating from the pulmonary veins: electrophysiological characteristics, pharmacological responses, and effects of radiofrequency ablation. Circulation 1999;100:1879–1886.
Waldo AL. Management of atrial fibrillation: the need for AFFIRMative action. Am J Cardiol 1999;84:698–700.
Schumacher B, Luderitz B. Rate issues in atrial fibrillation: Consequences of tachycardia and therapy for rate control. Am J Cardiol 1998;82:29N-36N.
Jensen SM, Bergfeldt L, Rosenqvist M. Long-term follow-up of patients treated by radiofrequency ablation of the atrioventricular junction. PACE 1995;18:1609–1614.
Rodriquez LM, Smeets JL, Xie B, et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol 1993;72:1137–1141.
Fitzpatrick AP. Impact on quality of life of His-Bundle catheter ablation and permanent pacing: measuring outcomes. Heart Failure 1997;13:43–46.
Goldman S, Johnson G, Cohn JN, et al., Mechanism of death in heart failure: the Vasodilator-Heart Failure Trial. Circulation 1993;87:VI 24–31.
Kjekshus J. Arrhythmias and mortality in congestive heart failure. Am J Cardiol 1990;65:421–481.
Randomized trial of low-does amiodarone in severe congestive heart failure. Lancet 1994;344:493–498.
Uretsky B, Sheahan RG. Primary prevention of sudden in heart failure: will the solution be shocking? J Am Coll Cardiol 1997;30:1589–1597.
Huang SKS, Messer JV, Denes P. Significance of ventricular tachycardia in idiopathic dilated cardiomyopathy: observation in 35 patients. Am J Cardiol 1982;51:507–512.
Meinertz T, Hofmann T, Kasper W, et al. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1984;53:902–907.
The Multi-center Post-Infarction Research Group (MPIP). Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331–336.
Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: two-year follow-up. Am J Cardiol 1984;54:31–36.
Bigger JT, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 1984;69:250–258.
Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the one-year mortality of dilated cardiomyopathy. Am J Cardiol 1984;54:147–152.
Gradman A, Deedwania P, Cody R, et al. Predictors of total mortality and sudden death in mild to moderate heart failure. J Am Coll Cardiol 1989;14:564–570.
Olshausen KV, Stienen U, Schwarz F, et al. Long-term prognositic significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy. Am J Cardiol 1988;61:146–151.
Packer M. Lack of relation between ventricular arrhythmias and sudden death in patients with chronic heart failure. Circulation 1992;85:150–156.
Gomes JA, Winters SL, Stewart D, et al. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol 1987;10:349–357.
Wilbur DJ, Olshansky B, Moran JF, et al. Electrophysiological testing and nonsustained ventricular tachycardia: use and limitations in patients with coronary artery disease and impaired ventricular function. Circulation 1990;82:350–358.
Gomes JA, Cain ME, Buxton AE, et al., Prediction of long-term outcomes by signalaveraged electrocardiography in patients with unsutained ventricular tachycardia, coronary artery disease, and left ventricular dysfunction. Circulation 2001;104:436–111.
Schmitt C, Barthel P, Ndrepepa G, et al. Value of programmed ventricular stimulation for prophylactic internal cardioverter-defibrillator implantation in postinfarction patients preselected by noninvasive risk stratifiers. J Am Coll Cardiol 2001;37:1901–1907.
Moss AJ, Hall J, Cannon DS, et al., Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933–1940.
Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 1999;341:1882–1890.
Poll DS, Marchlinski FE, Falcone RA, et al. Abnormal signal-averaged electrocardiograms in patients with nonischemic congestive cardiomyopathy. relationship to sustained ventricular tachyarrhythmias. Circulation 1985;6:1308–1313.
Mancini DM, Wong KL, Simson MB. Prognostic value of an abnormal signalaveraged electrocardiogram in patients with nonischemic congestive cardiomyopathy. Circulation 1993;87:1083–1092.
Poll DS, Marchlinski FE, Buxton AE, et al. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. Am J Cardiol 1986;58:992–997.
Middlekauff HR, Stevenson WG, Stevenson LW, et al., Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993;21:110–116.
Knight BP, Goyal R, Pelosi F, et al. Outcome of patients with nonischemic cardiomyopathy and unexplained syncope treated with implantable defibrillator. J Am Coll Cardiol 1999;33:1964–1970.
Doval HC, Nul DR, Grancelli HO, et al. Randomized trial of low-does amiodarone in severe congestive heart failure. Lancet 1994;344:493–498.
Singh SN, Fletcher RD, Fisher SG, et al., amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77–82.
Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667–674.
Carins JA, Connolly SJ, Roberts R, et al. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAMIAT. Lancet 1997;349:675–682.
Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349–1355.
Hjalmarson A, Prevention of sudden cardiac death with beta blockers. Clinical Cardiology 1999;22:V11-V15.
Group MERIT-HF Study, Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999;353:2001–2007.
Natale A, Newby KH, Pisan6 E, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol 2000;35:1898–1904.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Hsia, H.H. (2003). Evaluation of Palpitations. In: Jessup, M.L., Loh, E. (eds) Heart Failure. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-347-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-59259-347-7_6
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9759-5
Online ISBN: 978-1-59259-347-7
eBook Packages: Springer Book Archive